JP2013502446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502446A5 JP2013502446A5 JP2012525884A JP2012525884A JP2013502446A5 JP 2013502446 A5 JP2013502446 A5 JP 2013502446A5 JP 2012525884 A JP2012525884 A JP 2012525884A JP 2012525884 A JP2012525884 A JP 2012525884A JP 2013502446 A5 JP2013502446 A5 JP 2013502446A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- phenylsulfanyl
- dimethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 6
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002662 enteric coated tablet Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- JCYIWGHPBOTEDG-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.CCOC(=O)C(C)=C JCYIWGHPBOTEDG-UHFFFAOYSA-N 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23622309P | 2009-08-24 | 2009-08-24 | |
| US61/236,223 | 2009-08-24 | ||
| DKPA200900950 | 2009-08-24 | ||
| DKPA200900950 | 2009-08-24 | ||
| PCT/DK2010/050216 WO2011023194A2 (en) | 2009-08-24 | 2010-08-23 | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013502446A JP2013502446A (ja) | 2013-01-24 |
| JP2013502446A5 true JP2013502446A5 (https=) | 2013-09-19 |
Family
ID=43628463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525884A Pending JP2013502446A (ja) | 2009-08-24 | 2010-08-23 | １−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの新規組成物 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20120189697A1 (https=) |
| EP (1) | EP2470166B1 (https=) |
| JP (1) | JP2013502446A (https=) |
| KR (1) | KR20120065328A (https=) |
| CN (1) | CN102639117A (https=) |
| AU (1) | AU2010289022B2 (https=) |
| BR (1) | BR112012003280A2 (https=) |
| CA (1) | CA2769872A1 (https=) |
| CL (1) | CL2012000457A1 (https=) |
| CO (1) | CO6612204A2 (https=) |
| CR (1) | CR20120058A (https=) |
| DK (1) | DK2470166T3 (https=) |
| DO (1) | DOP2012000050A (https=) |
| EA (1) | EA021321B1 (https=) |
| ES (1) | ES2427628T3 (https=) |
| GE (1) | GEP20135950B (https=) |
| HR (1) | HRP20130819T1 (https=) |
| IL (1) | IL217914A0 (https=) |
| MA (1) | MA33598B1 (https=) |
| ME (1) | ME01602B (https=) |
| MX (1) | MX2012002199A (https=) |
| NZ (1) | NZ598083A (https=) |
| PL (1) | PL2470166T3 (https=) |
| PT (1) | PT2470166E (https=) |
| RS (1) | RS52959B (https=) |
| SG (1) | SG178325A1 (https=) |
| SI (1) | SI2470166T1 (https=) |
| SM (1) | SMT201300108B (https=) |
| TN (1) | TN2012000038A1 (https=) |
| UA (1) | UA105057C2 (https=) |
| WO (1) | WO2011023194A2 (https=) |
| ZA (1) | ZA201201360B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| JP5787882B2 (ja) * | 2010-04-30 | 2015-09-30 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| US8920840B2 (en) | 2010-04-30 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Enteric tablet |
| CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| EP3184104B1 (en) | 2015-12-23 | 2018-09-12 | Hexal AG | Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix |
| EP3184102A1 (en) | 2015-12-23 | 2017-06-28 | Hexal AG | Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound |
| WO2018002115A1 (en) | 2016-07-01 | 2018-01-04 | H. Lundbeck A/S | Vortioxetine dosing regimes for fast onset of antidepressant effect |
| WO2018065348A1 (en) | 2016-10-05 | 2018-04-12 | Hexal Ag | Novel enteric-coated tablet comprising vortioxetine |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN112006995A (zh) * | 2020-08-14 | 2020-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种氢溴酸伏硫西汀片的制备方法 |
| CN113350348B (zh) * | 2020-11-05 | 2022-03-01 | 东南大学 | 一种1-二苯甲基-4-甲基哌嗪类化合物在制备保护肠道屏障完整性药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514842D0 (en) * | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| US6866146B2 (en) | 2001-10-09 | 2005-03-15 | Christian M. Heesch | Protective case for string instruments |
| KR20070087678A (ko) * | 2004-12-20 | 2007-08-28 | 컬리지움 파마슈티칼, 인코포레이티드 | 수면 장애용 약제 조성물 |
| EP1888550B1 (en) * | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| WO2007015270A2 (en) * | 2005-08-02 | 2007-02-08 | Lupin Limited | Novel controlled release compositions of selective serotonin reuptake inhibitors |
| EP2044043B2 (en) * | 2006-06-16 | 2021-03-03 | H. Lundbeck A/S | 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
-
2010
- 2010-08-23 US US13/388,750 patent/US20120189697A1/en not_active Abandoned
- 2010-08-23 PL PL10805414T patent/PL2470166T3/pl unknown
- 2010-08-23 CN CN2010800376999A patent/CN102639117A/zh active Pending
- 2010-08-23 WO PCT/DK2010/050216 patent/WO2011023194A2/en not_active Ceased
- 2010-08-23 EA EA201290116A patent/EA021321B1/ru not_active IP Right Cessation
- 2010-08-23 BR BR112012003280A patent/BR112012003280A2/pt not_active IP Right Cessation
- 2010-08-23 NZ NZ598083A patent/NZ598083A/xx not_active IP Right Cessation
- 2010-08-23 PT PT108054149T patent/PT2470166E/pt unknown
- 2010-08-23 AU AU2010289022A patent/AU2010289022B2/en not_active Ceased
- 2010-08-23 GE GEAP201012633A patent/GEP20135950B/en unknown
- 2010-08-23 JP JP2012525884A patent/JP2013502446A/ja active Pending
- 2010-08-23 CA CA2769872A patent/CA2769872A1/en not_active Abandoned
- 2010-08-23 UA UAA201203101A patent/UA105057C2/uk unknown
- 2010-08-23 MX MX2012002199A patent/MX2012002199A/es active IP Right Grant
- 2010-08-23 RS RS20130404A patent/RS52959B/sr unknown
- 2010-08-23 HR HRP20130819AT patent/HRP20130819T1/hr unknown
- 2010-08-23 KR KR1020127004405A patent/KR20120065328A/ko not_active Withdrawn
- 2010-08-23 EP EP10805414.9A patent/EP2470166B1/en not_active Revoked
- 2010-08-23 ES ES10805414T patent/ES2427628T3/es active Active
- 2010-08-23 ME MEP-2013-99A patent/ME01602B/me unknown
- 2010-08-23 DK DK10805414.9T patent/DK2470166T3/da active
- 2010-08-23 SI SI201030343T patent/SI2470166T1/sl unknown
- 2010-08-23 SG SG2012008868A patent/SG178325A1/en unknown
-
2012
- 2012-01-25 TN TNP2012000038A patent/TN2012000038A1/en unknown
- 2012-02-02 IL IL217914A patent/IL217914A0/en unknown
- 2012-02-07 CR CR20120058A patent/CR20120058A/es unknown
- 2012-02-17 CO CO12028578A patent/CO6612204A2/es not_active Application Discontinuation
- 2012-02-22 CL CL2012000457A patent/CL2012000457A1/es unknown
- 2012-02-23 DO DO2012000050A patent/DOP2012000050A/es unknown
- 2012-02-23 ZA ZA2012/01360A patent/ZA201201360B/en unknown
- 2012-03-21 MA MA34709A patent/MA33598B1/fr unknown
-
2013
- 2013-09-30 SM SM201300108T patent/SMT201300108B/xx unknown
-
2015
- 2015-02-04 US US14/613,693 patent/US20150150867A1/en not_active Abandoned
- 2015-10-19 US US14/886,333 patent/US20160256398A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502446A5 (https=) | ||
| JP2014532638A5 (https=) | ||
| JP2011509295A5 (https=) | ||
| JP2013531028A5 (https=) | ||
| JP2017525712A5 (https=) | ||
| JP2011522816A5 (https=) | ||
| JP2010522244A5 (https=) | ||
| JP2010522242A5 (https=) | ||
| JP2015518885A5 (https=) | ||
| JP2010502762A5 (https=) | ||
| JP2013526482A5 (https=) | ||
| JP2012255026A5 (https=) | ||
| JP2010536849A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| JP2008515905A5 (https=) | ||
| JP2009537538A5 (https=) | ||
| JP2012505884A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| NZ598083A (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| JP2011510024A5 (https=) | ||
| JP2008533127A5 (https=) | ||
| JP2005530787A5 (https=) | ||
| JP2015508082A5 (https=) | ||
| JP2012523437A5 (https=) | ||
| AU2008309059A1 (en) | Pharmaceutical combination of Aliskiren and Valsartan |